Our group initially proposed a possible explanation as to why there are patients with immunocomplexes and high risk of thrombosis and patients without immune complexes and at low risk the existence of aPL with different affinities for B2GP1 in each patient. The gene discussed is APOH; the disease is Venous thrombosis.